Antony Loebel

Summary

Publications

  1. doi request reprint Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study
    Antony Loebel
    Sunovion Pharmaceuticals Inc, One Bridge Plaza North, Ste 510, Fort Lee, NJ 07024
    J Clin Psychiatry 77:1672-1680. 2016
  2. pmc Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
    Antony Loebel
    Sunovion Pharmaceuticals Inc, Fort Lee, NJ, USA
    BMC Psychiatry 15:271. 2015
  3. doi request reprint Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study
    Antony Loebel
    Sunovion Pharmaceuticals Inc, Marlborough, MA, USA Sunovion Pharmaceuticals Inc, Fort Lee, NJ, USA Electronic address
    J Affect Disord 186:376-82. 2015
  4. pmc Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
    George Awad
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    BMC Psychiatry 14:53. 2014
  5. pmc Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
    Antony D Loebel
    1 Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts, USA
    CNS Spectr 19:197-205. 2014
  6. doi request reprint Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study
    Antony Loebel
    Sunovion Pharmaceuticals Inc, Ft Lee, NJ 07024, USA
    Schizophr Res 147:95-102. 2013
  7. doi request reprint Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial
    Antony Loebel
    Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
    Schizophr Res 145:101-9. 2013
  8. doi request reprint Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release
    Krithika Rajagopalan
    Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
    J Med Econ 16:987-96. 2013
  9. pmc Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials
    Krithika Rajagopalan
    Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
    BMC Psychiatry 16:157. 2016
  10. doi request reprint Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression
    Joseph Calabrese
    aBipolar Disorders Research Center, Cleveland, Ohio bHealth Economics and Outcomes Research, Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts cOutcomes Research, Evidera, Bethesda, Maryland dResearch and Development, Sunovion Pharmaceuticals Inc, Fort Lee, New Jersey, USA
    Int Clin Psychopharmacol 31:147-54. 2016

Collaborators

Detail Information

Publications20

  1. doi request reprint Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study
    Antony Loebel
    Sunovion Pharmaceuticals Inc, One Bridge Plaza North, Ste 510, Fort Lee, NJ 07024
    J Clin Psychiatry 77:1672-1680. 2016
    ..To assess the effect of dose increase in adult patients with schizophrenia who demonstrate inadequate initial response to standard-dose lurasidone and to evaluate the efficacy of low-dose lurasidone in adult patients with schizophrenia...
  2. pmc Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
    Antony Loebel
    Sunovion Pharmaceuticals Inc, Fort Lee, NJ, USA
    BMC Psychiatry 15:271. 2015
    ..The purpose of this report is to describe the background, rationale and design of this study that included a novel method for the assessment of the potential for dose-response in early non-responding patients with schizophrenia...
  3. doi request reprint Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study
    Antony Loebel
    Sunovion Pharmaceuticals Inc, Marlborough, MA, USA Sunovion Pharmaceuticals Inc, Fort Lee, NJ, USA Electronic address
    J Affect Disord 186:376-82. 2015
    ..In this post-hoc analysis, rates of remission and recovery were evaluated in patients with bipolar depression treated with lurasidone...
  4. pmc Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
    George Awad
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    BMC Psychiatry 14:53. 2014
    ..This analysis evaluated HRQoL changes among patients with schizophrenia switched from their current antipsychotic to lurasidone...
  5. pmc Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
    Antony D Loebel
    1 Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts, USA
    CNS Spectr 19:197-205. 2014
    ....
  6. doi request reprint Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study
    Antony Loebel
    Sunovion Pharmaceuticals Inc, Ft Lee, NJ 07024, USA
    Schizophr Res 147:95-102. 2013
    ..To evaluate the relapse prevention efficacy of lurasidone compared with quetiapine XR (QXR) in adults patients with schizophrenia...
  7. doi request reprint Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial
    Antony Loebel
    Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
    Schizophr Res 145:101-9. 2013
    ..This study was designed to evaluate the short-term efficacy and safety of once-daily lurasidone (80 mg/day and 160 mg/day) in the treatment of an acute exacerbation of schizophrenia...
  8. doi request reprint Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release
    Krithika Rajagopalan
    Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
    J Med Econ 16:987-96. 2013
    ..To model the economic impact of annual relapses/relapse-related hospitalizations among adults with schizophrenia treated with lurasidone or quetiapine extended-release (XR)...
  9. pmc Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials
    Krithika Rajagopalan
    Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
    BMC Psychiatry 16:157. 2016
    ..The objective of this study was to examine the direct and indirect effect (mediated through improvement in depression symptoms) of lurasidone in improving patient HRQoL...
  10. doi request reprint Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression
    Joseph Calabrese
    aBipolar Disorders Research Center, Cleveland, Ohio bHealth Economics and Outcomes Research, Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts cOutcomes Research, Evidera, Bethesda, Maryland dResearch and Development, Sunovion Pharmaceuticals Inc, Fort Lee, New Jersey, USA
    Int Clin Psychopharmacol 31:147-54. 2016
    ..05), and through the visual display of cumulative distribution functions. Short-term lurasidone monotherapy and adjunctive therapy is associated with a clinically meaningful improvement in HRQoL in patients with bipolar depression...
  11. pmc The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial
    Krithika Rajagopalan
    Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
    Int J Bipolar Disord 4:7. 2016
    ....
  12. doi request reprint Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression
    Krithika Rajagopalan
    a a Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
    J Med Econ 18:821-7. 2015
    ..The objective of this analysis was to estimate the cost-effectiveness of lurasidone and quetiapine XR in patients with bipolar depression...
  13. doi request reprint The development of lurasidone for bipolar depression
    Antony Loebel
    Sunovion Pharmaceuticals Inc, Fort Lee, New Jersey, and Marlborough, Massachusetts
    Ann N Y Acad Sci 1358:95-104. 2015
    ..The approval of lurasidone expands available treatment options for patients with bipolar depression and provides a therapy with an overall favorable risk-benefit profile. ..
  14. doi request reprint Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial
    Mitsutaka Nakamura
    Dainippon Sumitomo Pharma America Inc, Fort Lee, NJ 07024, USA
    J Clin Psychiatry 70:829-36. 2009
    ..The objective of the study was to evaluate the safety and efficacy of lurasidone in patients hospitalized for an acute exacerbation of DSM-IV-defined schizophrenia...
  15. pmc Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults
    Kenneth S Koblan
    Sunovion Pharmaceuticals, Marlborough, MA, USA
    Neuropsychopharmacology 40:2745-52. 2015
    ..This study provides preliminary evidence that once-daily dosing with dasotraline, a long-acting, dual monoamine reuptake inhibitor, may be a safe and efficacious treatment for adult ADHD. ..
  16. pmc Lurasidone for the Treatment of Irritability Associated with Autistic Disorder
    Antony Loebel
    Sunovion Pharmaceuticals, Inc, Fort Lee, NJ, USA
    J Autism Dev Disord 46:1153-63. 2016
    ....
  17. pmc Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
    Jonathan M Meyer
    aDepartment of Psychiatry, University of California, San Diego, California bSunovion Pharmaceuticals Inc, Fort Lee, New Jersey, USA
    Int Clin Psychopharmacol 30:342-50. 2015
    ..In summary, a low potential for clinically significant weight gain was observed in patients with schizophrenia treated continuously with lurasidone for 12 months...
  18. pmc Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
    Seth C Hopkins
    Sunovion Pharmaceuticals Inc, 84 Waterford Drive, Marlborough, MA, 01752, USA
    Clin Drug Investig 36:137-46. 2016
    ..Here we relate the pharmacokinetics and pharmacodynamics of dasotraline to reduction in ADHD symptoms based on simulated clinical trial outcomes...
  19. pmc Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
    Krithika Rajagopalan
    Health Economics and Outcomes Research, Sunovion Pharmaceuticals Inc, 84 Waterford Drive, Marlborough, MA, 01752, USA
    Pharmacoeconomics 34:709-21. 2016
    ..We conducted a cost-utility analysis of lurasidone versus aripiprazole from the perspective of healthcare services, using Scotland and Wales as specific case studies...
  20. doi request reprint Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis
    Krithika Rajagopalan
    a Global Health Economics and Outcomes Research, Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
    Curr Med Res Opin . 2017
    ..To compare adherence with lurasidone to other oral atypical antipsychotics among Medicaid- and commercially-insured patients with schizophrenia...